吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌.pdf

《吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、现代生物医学进展www．shengwuyixue．eomProgressinModernBiomedicineVoL12NO．9MAR．2012吉西他滨联合顺铂序贯吉非替尼治疗晚期tH,细胞肺癌过雪丹吴福林陈暑波徐伟黄庆△(1无锡市第二人民医院肿瘤科江苏无锡214002；2无锡市人民医院内科江苏无锡214002)摘要目的：观察吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌的疗效与毒副反应。方法：71例经病理学诊断的晚期(IIIb．1V期)非小细胞肺癌患者。随机分成两组，观察组给予吉西他滨加顺铂化疗，序贯吉非替尼。对照组给予吉西他滨加顺铂化疗。结果

2、：两组有效率(RR)为36．1％VS14．3％(P=0．0362)；疾病控制率(DCR)比较x2：14．782，P<0．001；中位生存期(MST)为12．1月VS10．8月(P

3、binCombinedWithcisplatinsequentialtoGefitinibintheTreatmentofAdvancedNon,smallCenLungCancerGUOXue-dan；UFu-lin1,CHENShu—bo；XUweLHUANGQin营rJDepartmentofOncology,WuxiNo．2People'sHospital,Wuxi214002,China；2DepartmentofInternal，WuxiPeople'sHospital,Wuxi214002,China)ABSTRACTObjectiv

4、e：Tostudywiththeclinicaleficacyandtoxicityforadcancedno-smallcelllungcancerusingGemcitabinCombinedWithcisplatinsequentialtoGefitinibrigemen．Methods：54caseswithpathologicaldignosisofadvancedno—smallcelllungcancer(IIIb-IV)weredividedstochasticallyintogemcitabincombinedwithcispla

5、finfollowedbygefitinibtreatmentgroupandgemc—itabincombinedwithcisplatingroup．Results：In71cases，theoverallresponserates(RIoftwogroupswere36．1％VS14-3％(P=0．0362)；TheDCRoftwogroupswere83．3％VS42．9％(x2-．_14．782，P<0．001)；Themediansurvialtime(MST)was12．1monthsand10．8monthsrespectively

6、(P<0．05)；There’Snostatisticsdiferencebetweentwogroupsbutrashanddiarrhea．Conclusion：Goodclinicalef-ficacyandsafetywereachievedinthetherapyofadcancedno-smallcelllungcancerusingGemcitabinCombinedWithcisplatinsequen·tialtoGefitinibrigemen．Itisworthyoffurtherenlargedsampleresearch．

7、Keywords：Gemcitabin；Cisplatin；Gefitinib；Sequentialadministration；Non-smallcelllungcancerChineseLibraryClassification(CLC)：R734．2Documentcode：AArticleID：1673—6273(2012、09—1696_o3非小细胞肺癌(no．smallcelllungcancer，NSCLC)占肺癌的料见表1。80％。65％的患者诊断时已为局部晚期或晚期，临床采用以铂类1．2治疗方法为基础的药物二线化疗仅能使IIIb-

8、IV期的患者死亡风险下降观察组：吉西他滨1000mg／m2，静脉滴注，第1，8天；顺铂26．32％t“。自从分子靶向治疗进